Danaher Co. (NYSE:DHR) Shares Sold by UMB Bank n.a.

UMB Bank n.a. trimmed its holdings in Danaher Co. (NYSE:DHR) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 110,005 shares of the conglomerate’s stock after selling 3,090 shares during the quarter. UMB Bank n.a.’s holdings in Danaher were worth $25,252,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. purchased a new stake in Danaher in the fourth quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the 3rd quarter worth about $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter worth about $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 1.4 %

Shares of NYSE DHR opened at $238.41 on Monday. The company has a 50 day simple moving average of $234.85 and a 200-day simple moving average of $253.42. The company has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 EPS. On average, equities research analysts predict that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DHR. UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. KeyCorp increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus increased their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird decreased their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.